Piramal Pharma (NSE:PPLPHARMA) COGS-to-Revenue : 0.40 (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma COGS-to-Revenue?

Piramal Pharma's Cost of Goods Sold for the three months ended in Mar. 2024 was ₹10,144 Mil. Its Revenue for the three months ended in Mar. 2024 was ₹25,524 Mil.

Piramal Pharma's COGS to Revenue for the three months ended in Mar. 2024 was 0.40.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Piramal Pharma's Gross Margin % for the three months ended in Mar. 2024 was 60.26%.

Piramal Pharma COGS-to-Revenue Historical Data

The historical data trend for Piramal Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma COGS-to-Revenue Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

COGS-to-Revenue

0.43

0.44

0.38

0.36

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial							0.39	0.36	0.33	0.34	0.40

Piramal Pharma COGS-to-Revenue Calculation

Piramal Pharma's COGS to Revenue for the fiscal year that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	29540	/	81711.6
	=	0.36

Piramal Pharma's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	10143.9	/	25523.6
	=	0.40

Piramal Pharma (NSE:PPLPHARMA) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Piramal Pharma's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	10143.9 / 25523.6
	=	60.26 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Piramal Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma (NSE:PPLPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » COGS-to-Revenue

Traded in Other Exchanges

543635:India

Address

Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramal.com

Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines